Sign in or create an account to add this stock to your watchlist.
About Emergent Biosolutions (NYSE:EBS)
Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company offers BioThrax, an anthrax vaccine; ACAM2000, a Smallpox Vaccine; Raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. It also provides reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. The company's product candidates include NuThrax, a next generation anthrax vaccine; VLA1601, for the treatment of Zika virus; UNI-FLU, an influenza vaccine; EBX-205, an oral therapeutic to treat acute bacterial skin and skin structure infection; GC-072 for treating Burkholderia pseudomallei infection; EBI-001, a pan respiratory antiviral; FLU-IG (NP025) for the treatment of seasonal influenza; ZIKA-IG (NP024) for Zika infections; and FILOV (NP026) for treating treat hemorrhagic fever caused by Filoviruses. In addition, it provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNYSE:EBS
CUSIP29089Q10
Phone240-631-3200
Debt
Debt-to-Equity Ratio0.02
Current Ratio5.49
Quick Ratio3.70
Price-To-Earnings
Trailing P/E Ratio26.64
Forward P/E Ratio21.14
P/E Growth1.08
Sales & Book Value
Annual Sales$560.87 million
Price / Sales4.45
Cash Flow$2.7452 per share
Price / Cash18.25
Book Value$17.69 per share
Price / Book2.83
Profitability
EPS (Most Recent Fiscal Year)$1.90
Net Income$82.59 million
Net Margins11.96%
Return on Equity10.39%
Return on Assets7.74%
Miscellaneous
Employees1,256
Outstanding Shares49,820,000
Emergent Biosolutions (NYSE:EBS) Frequently Asked Questions
What is Emergent Biosolutions' stock symbol?
Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."
How will Emergent Biosolutions' stock buyback program work?
Emergent Biosolutions declared that its board has authorized a share buyback program on Friday, March 23rd 2018, which authorizes the company to repurchase $50,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.
How were Emergent Biosolutions' earnings last quarter?
Emergent Biosolutions Inc (NYSE:EBS) released its quarterly earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by $0.25. The biopharmaceutical company had revenue of $117.80 million for the quarter, compared to the consensus estimate of $140.42 million. Emergent Biosolutions had a return on equity of 10.39% and a net margin of 11.96%. Emergent Biosolutions's revenue for the quarter was up .8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.23 earnings per share. View Emergent Biosolutions' Earnings History.
When is Emergent Biosolutions' next earnings date?
What price target have analysts set for EBS?
4 brokerages have issued 12 month price objectives for Emergent Biosolutions' stock. Their predictions range from $53.00 to $60.00. On average, they anticipate Emergent Biosolutions' share price to reach $56.00 in the next twelve months. View Analyst Ratings for Emergent Biosolutions.
Who are some of Emergent Biosolutions' key competitors?
Some companies that are related to Emergent Biosolutions include Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), Dr. Reddy's Laboratories (RDY), Taro Pharmaceutical Industries (TARO), United Therapeutics (UTHR) and FibroGen (FGEN).
Who are Emergent Biosolutions' key executives?
Emergent Biosolutions' management team includes the folowing people:
- Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 60)
- Mr. Daniel J. Abdun-Nabi, CEO & Director (Age 63)
- Mr. Robert G. Kramer Sr., Pres & COO (Age 61)
- Mr. Adam R. Havey, Exec. VP of Bus. Operations (Age 47)
- Mr. Richard S. Lindahl, Exec. VP, CFO & Treasurer (Age 54)
Has Emergent Biosolutions been receiving favorable news coverage?
News articles about EBS stock have trended very positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Emergent Biosolutions earned a daily sentiment score of 0.69 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 47.83 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Emergent Biosolutions' major shareholders?
Emergent Biosolutions' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.97%), Dimensional Fund Advisors LP (4.43%), Summit Trail Advisors LLC (2.77%), Royal Bank of Canada (2.35%), Millennium Management LLC (1.84%) and Russell Investments Group Ltd. (1.14%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.
Which institutional investors are selling Emergent Biosolutions stock?
EBS stock was sold by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company , LSV Asset Management, Federated Investors Inc. PA, Amundi Pioneer Asset Management Inc., FIL Ltd, Royal Bank of Canada, Guggenheim Capital LLC and Fisher Asset Management LLC. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Ronald Richard and Zsolt Harsanyi. View Insider Buying and Selling for Emergent Biosolutions.
Which institutional investors are buying Emergent Biosolutions stock?
EBS stock was bought by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Matarin Capital Management LLC, Prudential Financial Inc., Millennium Management LLC, Russell Investments Group Ltd., Monarch Partners Asset Management LLC, UBS Group AG and Allianz Asset Management GmbH. View Insider Buying and Selling for Emergent Biosolutions.
How do I buy shares of Emergent Biosolutions?
Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Emergent Biosolutions' stock price today?
One share of EBS stock can currently be purchased for approximately $50.10.
How big of a company is Emergent Biosolutions?
Emergent Biosolutions has a market capitalization of $2.54 billion and generates $560.87 million in revenue each year. The biopharmaceutical company earns $82.59 million in net income (profit) each year or $1.90 on an earnings per share basis. Emergent Biosolutions employs 1,256 workers across the globe.
How can I contact Emergent Biosolutions?
Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]
MarketBeat Community Rating for Emergent Biosolutions (EBS)
MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe EBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Emergent Biosolutions (NYSE:EBS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Emergent Biosolutions in the last 12 months. Their average twelve-month price target is $56.00, suggesting that the stock has a possible upside of 11.78%. The high price target for EBS is $60.00 and the low price target for EBS is $53.00. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.50 | 2.67 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $56.00 | $56.00 | $50.3333 | $45.00 |
| Price Target Upside: | 11.78% upside | 2.71% upside | 0.96% downside | 11.25% upside |
Emergent Biosolutions (NYSE:EBS) Consensus Price Target History
Emergent Biosolutions (NYSE:EBS) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Emergent Biosolutions (NYSE:EBS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Emergent Biosolutions (NYSE EBS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 16.50%
Institutional Ownership Percentage: 82.70%
Emergent Biosolutions (NYSE EBS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/17/2018 | Ronald Richard | Director | Sell | 7,893 | $55.00 | $434,115.00 | 31,303 |  |
| 3/12/2018 | Adam Havey | EVP | Sell | 5,842 | $52.82 | $308,574.44 | 35,756 | |
| 3/1/2018 | Adam Havey | EVP | Sell | 1,898 | $49.50 | $93,951.00 | | |
| 1/22/2018 | Jerome M Hauer | Director | Sell | 5,152 | $50.91 | $262,288.32 | 23,797 | |
| 1/2/2018 | Daniel Abdun-Nabi | CEO | Sell | 21,906 | $47.91 | $1,049,516.46 | 226,040 | |
| 12/13/2017 | Daniel Abdun-Nabi | CEO | Sell | 20,000 | $45.99 | $919,800.00 | 224,134 | |
| 12/12/2017 | Ronald Richard | Director | Sell | 23,681 | $45.02 | $1,066,118.62 | 47,091 | |
| 12/7/2017 | Zsolt Harsanyi | Director | Sell | 7,000 | $42.47 | $297,290.00 | 37,077 | |
| 11/29/2017 | Fuad El-Hibri | Chairman | Sell | 47,983 | $41.88 | $2,009,528.04 | 1,550,216 | |
| 11/14/2017 | Fuad El-Hibri | Chairman | Sell | 40,000 | $40.37 | $1,614,800.00 | | |
| 11/7/2017 | George A Joulwan | Director | Sell | 14,251 | $41.24 | $587,711.24 | 34,323 | |
| 11/3/2017 | Daniel Abdun-Nabi | CEO | Sell | 31,508 | $42.77 | $1,347,597.16 | 215,642 | |
| 9/29/2017 | Fuad El-Hibri | Chairman | Sell | 25,000 | $40.50 | $1,012,500.00 | 1,555,216 | |
| 9/28/2017 | Ronald Richard | Director | Sell | 22,415 | $40.00 | $896,600.00 | 24,676 | |
| 9/27/2017 | Adam Havey | EVP | Sell | 7,885 | $39.50 | $311,457.50 | 33,931 | |
| 9/27/2017 | Daniel Abdun-Nabi | CEO | Sell | 15,000 | $39.92 | $598,800.00 | 219,134 | |
| 9/27/2017 | Fuad El-Hibri | Chairman | Sell | 25,000 | $39.50 | $987,500.00 | 1,555,216 | |
| 9/27/2017 | Ronald Richard | Director | Sell | 1,266 | $40.00 | $50,640.00 | 24,676 | |
| 9/14/2017 | Fuad El-Hibri | Chairman | Sell | 25,000 | $38.50 | $962,500.00 | 1,603,763 | |
| 9/8/2017 | Adam Havey | EVP | Sell | 7,885 | $37.06 | $292,218.10 | 33,931 | |
| 9/7/2017 | Fuad El-Hibri | Chairman | Sell | 16,439 | $37.50 | $616,462.50 | 1,605,216 | |
| 9/5/2017 | Fuad El-Hibri | Chairman | Sell | 3,100 | $37.50 | $116,250.00 | 1,621,655 | |
| 8/31/2017 | Daniel Abdun-Nabi | CEO | Sell | 15,000 | $37.21 | $558,150.00 | 219,134 | |
| 8/31/2017 | Fuad El-Hibri | Chairman | Sell | 5,461 | $37.50 | $204,787.50 | 1,624,755 | |
| 8/15/2017 | Jerome M Hauer | Director | Sell | 10,776 | $35.83 | $386,104.08 | 29,421 | |
| 7/27/2017 | Fuad El-Hibri | Chairman | Sell | 25,000 | $36.50 | $912,500.00 | 1,630,216 | |
| 7/20/2017 | Fuad El-Hibri | Chairman | Sell | 25,000 | $35.50 | $887,500.00 | 1,655,216 | |
| 4/3/2017 | Adam Havey | EVP | Sell | 11,419 | $28.62 | $326,811.78 | 26,046 | |
| 3/8/2017 | Jerome M Hauer | Director | Sell | 2,576 | $31.27 | $80,551.52 | 17,404 | |
| 1/17/2017 | Adam Havey | EVP | Sell | 8,438 | $29.75 | $251,030.50 | 41,424 | |
| 1/17/2017 | Sue Bailey | Director | Sell | 19,424 | $29.78 | $578,446.72 | 34,637 | |
| 1/10/2017 | Daniel Abdun-Nabi | Insider | Sell | 28,240 | $31.28 | $883,347.20 | 172,945 | |
| 12/13/2016 | Ronald Richard | Director | Sell | 5,900 | $34.09 | $201,131.00 | 19,870 | |
| 6/6/2016 | George A Joulwan | Director | Sell | 4,700 | $44.12 | $207,364.00 | 20,785 | |
| 6/1/2016 | Daniel Abdun-Nabi | CEO | Sell | 8,699 | $43.74 | $380,494.26 | 170,966 | |
| 5/27/2016 | Fuad El-Hibri | Major Shareholder | Sell | 9,835 | $43.50 | $427,822.50 | 1,649,073 | |
| 5/26/2016 | Fuad El-Hibri | Major Shareholder | Sell | 39,759 | $43.13 | $1,714,805.67 | 1,698,667 | |
| 5/25/2016 | Fuad El-Hibri | Major Shareholder | Sell | 85,000 | $42.52 | $3,614,200.00 | 1,719,073 | |
| 5/25/2016 | Zsolt Harsanyi | Director | Sell | 27,867 | $42.33 | $1,179,610.11 | 41,685 | |
| 5/24/2016 | Fuad El-Hibri | Chairman | Sell | 20,000 | $42.26 | $845,200.00 | 1,719,073 | |
| 5/23/2016 | Fuad El-Hibri | Chairman | Sell | 45,000 | $42.62 | $1,917,900.00 | 1,719,073 | |
| 5/20/2016 | Daniel Abdun-Nabi | CEO | Sell | 8,701 | $42.00 | $365,442.00 | 179,665 | |
| 5/19/2016 | Jerome M Hauer | Director | Sell | 3,134 | $41.22 | $129,183.48 | 20,085 | |
| 5/13/2016 | Louis W Sullivan | Director | Sell | 47,631 | $39.21 | $1,867,611.51 | 28,800 | |
| 5/12/2016 | Fuad El-Hibri | Major Shareholder | Sell | 25,000 | $38.71 | $967,750.00 | 1,699,073 | |
| 5/12/2016 | Jerome M Hauer | Director | Sell | 4,700 | $38.50 | $180,950.00 | 18,800 | |
| 5/11/2016 | Louis W Sullivan | Director | Sell | 9,969 | $39.25 | $391,283.25 | 38,469 | |
| 4/22/2016 | Fuad El-Hibri | Major Shareholder | Sell | 4,209 | $40.50 | $170,464.50 | 1,724,073 | |
| 4/18/2016 | Daniel Abdun-Nabi | CEO | Sell | 8,702 | $40.17 | $349,559.34 | 194,319 | |
| 4/18/2016 | Fuad El-Hibri | Major Shareholder | Sell | 20,791 | $40.50 | $842,035.50 | 1,728,282 | |
| 4/6/2016 | Fuad El-Hibri | Major Shareholder | Sell | 50,000 | $39.00 | $1,950,000.00 | 1,774,073 | |
| 4/6/2016 | Robert Kramer | EVP | Sell | 21,786 | $38.90 | $847,475.40 | 77,551 | |
| 4/4/2016 | Robert Kramer | EVP | Sell | 21,788 | $36.90 | $803,977.20 | 80,597 | |
| 4/1/2016 | Robert Kramer | EVP | Sell | 43,572 | $35.56 | $1,549,420.32 | 91,607 | |
| 3/14/2016 | Adam Havey | EVP | Sell | 4,359 | $33.96 | $148,031.64 | 39,163 | |
| 3/14/2016 | Jerome M Hauer | Director | Sell | 2,350 | $33.88 | $79,618.00 | 14,100 | |
| 3/11/2016 | Adam Havey | EVP | Sell | 11,112 | $33.84 | $376,030.08 | 54,254 | |
| 3/11/2016 | Louis W Sullivan | Director | Sell | 14,879 | $34.03 | $506,332.37 | 43,379 | |
| 3/7/2016 | Marvin L White | Director | Sell | 33,134 | $35.42 | $1,173,606.28 | 41,100 | |
| 1/4/2016 | Sue Bailey | Director | Sell | 11,520 | $38.79 | $446,860.80 | 28,500 | |
| 12/30/2015 | Ronald Richard | Director | Sell | 21,600 | $40.00 | $864,000.00 | 13,733 | |
| 12/24/2015 | Daniel Abdun-Nabi | CEO | Sell | 63,209 | $39.06 | $2,468,943.54 | 185,368 | |
| 11/19/2015 | Fuad El-Hibri | major shareholder | Sell | 17,871 | $37.50 | $670,162.50 | 1,852,284 | |
| 11/13/2015 | Fuad El-Hibri | major shareholder | Sell | 13,013 | $36.50 | $474,974.50 | 1,842,255 | |
| 11/12/2015 | Barry Labinger | EVP | Sell | 36,126 | $35.64 | $1,287,530.64 | 28,558 | |
| 11/9/2015 | Fuad El-Hibri | major shareholder | Sell | 13,225 | $35.50 | $469,487.50 | 1,835,268 | |
| 11/6/2015 | Fuad El-Hibri | major shareholder | Sell | 13,450 | $34.50 | $464,025.00 | 1,828,493 | |
| 11/3/2015 | Fuad El-Hibri | major shareholder | Sell | 13,689 | $33.50 | $458,581.50 | 1,821,943 | |
| 9/11/2015 | Sue Bailey | Director | Sell | 6,080 | $32.37 | $196,809.60 | 28,500 | |
| 8/13/2015 | George A Joulwan | Director | Sell | 7,200 | $34.72 | $249,984.00 | | |
| 7/20/2015 | Fuad El-Hibri | Chairman | Sell | 234 | $34.50 | $8,073.00 | | |
| 7/13/2015 | Ronald Richard | Director | Sell | 4,922 | $34.00 | $167,348.00 | | |
| 6/29/2015 | Ronald Richard | Director | Sell | 4,923 | $32.76 | $161,277.48 | | |
| 6/22/2015 | Fuad El-Hibri | Major Shareholder | Sell | 74,564 | $32.60 | $2,430,786.40 | | |
| 6/16/2015 | Louis W Sullivan | Director | Sell | 13,457 | $31.33 | $421,607.81 | | |
| 6/15/2015 | Adam Havey | EVP | Sell | 36,298 | $31.55 | $1,145,201.90 | | |
| 6/15/2015 | Fuad El-Hibri | Major Shareholder | Sell | 45,436 | $32.18 | $1,462,130.48 | | |
| 1/20/2015 | Fuad El-Hibri | Major Shareholder | Sell | 15,325 | $27.67 | $424,042.75 | | |
| 12/26/2014 | Ronald Richard | Director | Sell | 5,000 | $28.00 | $140,000.00 | | |
| 12/17/2014 | Ronald Richard | Director | Sell | 5,000 | $27.00 | $135,000.00 | | |
| 12/11/2014 | Fuad El-Hibri | Major Shareholder | Sell | 119,341 | $26.00 | $3,102,866.00 | | |
| 11/28/2014 | Fuad El-Hibri | Major Shareholder | Sell | 34,577 | $25.00 | $864,425.00 | | |
| 11/25/2014 | Fuad El-Hibri | Major Shareholder | Sell | 9,014 | $25.00 | $225,350.00 | | |
| 11/25/2014 | Zsolt Harsanyi | Director | Sell | 8,000 | $24.82 | $198,560.00 | | |
| 11/12/2014 | Fuad El-Hibri | Major Shareholder | Sell | 2,311 | $25.00 | $57,775.00 | | |
| 11/7/2014 | Robert Kramer | CFO | Sell | 2,625 | $24.00 | $63,000.00 | | |
| 4/16/2014 | Robert Kramer | CFO | Sell | 50,189 | $24.34 | $1,221,600.26 | 62,183 | |
| 3/12/2014 | Adam Havey | EVP | Sell | 11,562 | $27.50 | $317,955.00 | 36,145 | |
| 3/11/2014 | Adam Havey | EVP | Sell | 17,655 | $26.96 | $475,978.80 | 36,920 | |
(Data available from 1/1/2013 forward)
Emergent Biosolutions (NYSE EBS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | The latest outbreak of a deadly virus has scientists racing to create a vaccine
finance.yahoo.com - May 25 at 8:27 AM |
 | Consolidated Research: 2018 Summary Expectations for PGT, National Commerce, CrossAmerica Partners
www.nasdaq.com - May 24 at 8:28 AM |
| Consolidated Research: 2018 Summary Expectations for PGT, National Commerce, CrossAmerica Partners LP, Destination XL Group, Allegiance Bancshares, and Emergent Biosolutions — Fundamental Analysis, Key Performance Indications
finance.yahoo.com - May 24 at 8:28 AM |
| U.S. biotechs to speed work on Nipah vaccine as virus hits India
finance.yahoo.com - May 24 at 8:28 AM |
 | CEPI Awards $25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus Vaccine
feeds.benzinga.com - May 24 at 6:24 AM |
 | Analysts Expect Emergent BioSolutions (EBS) Will Post Quarterly Sales of $209.30 Million
www.americanbankingnews.com - May 19 at 2:30 AM |
| VALNEVA Reports Strong Q1 Results and Continues to Advance Key R&D Programs
www.nasdaq.com - May 17 at 6:10 PM |
| Emergent BioSolutions (EBS) Expected to Post Earnings of $1.02 Per Share
www.americanbankingnews.com - May 17 at 5:18 PM |
| Emergent BioSolutions (EBS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 13 at 9:49 AM |
| Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 24, 2018 at 9:00 AM EDT; Webcast Will Be Available
finance.yahoo.com - May 10 at 5:45 PM |
 | Emergent BioSolutions Moves Things Around
www.fool.com - May 8 at 4:54 PM |
 | Emergent BioSolutions' (EBS) CEO Dan Abdun Nabi on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 8:26 AM |
 | BRIEF-Emergent BioSolutions Reports Q1 Adjusted Loss Per Share $0.03
www.reuters.com - May 4 at 8:26 AM |
| Emergent Biosolutions: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 8:26 AM |
| Edited Transcript of EBS earnings conference call or presentation 3-May-18 9:00pm GMT
finance.yahoo.com - May 4 at 8:26 AM |
| Emergent BioSolutions (EBS) Releases Earnings Results, Misses Estimates By $0.40 EPS
www.americanbankingnews.com - May 4 at 12:47 AM |
| Emergent BioSolutions Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 3 at 5:16 PM |
| Jazz Pharmaceuticals (JAZZ) Q1 Earnings: What's in Store?
www.nasdaq.com - May 2 at 5:28 PM |
| Emergent BioSolutions (EBS) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 1 at 12:26 PM |
| Emergent BioSolutions (EBS) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 30 at 12:50 PM |
| Emergent Biosolutions' Stock Run Can't Continue Forever, Wells Fargo Says In Downgrade
finance.yahoo.com - April 26 at 8:24 AM |
| Emergent BioSolutions (EBS) to Release Earnings on Thursday
www.americanbankingnews.com - April 26 at 1:56 AM |
| Emergent BioSolutions (EBS) Receives "Market Perform" Rating from Wells Fargo
www.americanbankingnews.com - April 25 at 10:49 AM |
| Emergent BioSolutions (EBS) Lowered to Market Perform at Wells Fargo
www.americanbankingnews.com - April 24 at 9:06 PM |
| Emergent BioSolutions (EBS) Director Sells $434,115.00 in Stock
www.americanbankingnews.com - April 19 at 7:34 PM |
| Emergent BioSolutions to Release First Quarter 2018 Financial Results and Conduct a Conference Call on May 3, 2018
finance.yahoo.com - April 19 at 8:26 AM |
| Emergent BioSolutions (EBS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 18 at 8:41 AM |
 | Emergent BioSolutions to enter 5 new countries with anthrax vaccine
www.bizjournals.com - April 13 at 5:23 PM |
| Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorisation of BioThrax in European Countries
finance.yahoo.com - April 12 at 8:54 AM |
| Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorization of BioThrax in European Countries
finance.yahoo.com - April 12 at 8:54 AM |
 | Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why
www.msn.com - April 7 at 8:39 AM |
| Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why
finance.yahoo.com - April 7 at 8:39 AM |
| Emergent Biosolutions (EBS) Lifted to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - March 31 at 12:16 PM |
| Emergent Biosolutions (EBS) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 28 at 7:37 PM |
 | Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company's Growth ...
globenewswire.com - March 28 at 8:39 AM |
| BRIEF-Emergent BioSolutions Appoints Richard Lindahl As New Executive Vice President And Chief Financial Officer
www.reuters.com - March 28 at 8:39 AM |
| New operating chief at Emergent Bio
seekingalpha.com - March 26 at 5:09 PM |
| Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company’s Growth Strategy
finance.yahoo.com - March 26 at 5:09 PM |
| Why Is Emergent Biosolutions (EBS) Up 8% Since Its Last Earnings Report?
finance.yahoo.com - March 26 at 8:32 AM |
| Singular Research Raises Emergent Biosolutions (EBS) Price Target to $60.00
www.americanbankingnews.com - March 24 at 9:28 PM |
| Emergent Biosolutions Inc (EBS) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 24 at 8:04 AM |
| Emergent Biosolutions (EBS) to Buyback $50.00 million in Outstanding Shares
www.americanbankingnews.com - March 23 at 11:26 AM |
 | Emergent BioSolutions (EBS) to Implement Stock Repurchase Program for up to $50 Million
www.streetinsider.com - March 22 at 5:28 PM |
| Emergent BioSolutions to Implement Stock Repurchase Program for up to $50 Million of Its Common Stock
finance.yahoo.com - March 22 at 5:28 PM |
| Emergent BioSolutions Reaches Analyst Target Price - Nasdaq
www.nasdaq.com - March 22 at 8:37 AM |
| Edited Transcript of EBS earnings conference call or presentation 22-Feb-18 10:00pm GMT
finance.yahoo.com - March 21 at 5:29 PM |
| Emergent Biosolutions Inc (EBS) EVP Adam Havey Sells 5,842 Shares
www.americanbankingnews.com - March 13 at 7:52 PM |
| Arizona State Retirement System Has $2.75 Million Stake in Emergent Biosolutions Inc (EBS)
www.americanbankingnews.com - March 6 at 4:36 AM |
| Emergent Biosolutions Inc (EBS) Shares Sold by Kennedy Capital Management Inc.
www.americanbankingnews.com - March 5 at 11:39 AM |
| Emergent Biosolutions (EBS) Upgraded by ValuEngine to "Buy"
www.americanbankingnews.com - March 4 at 7:48 PM |
Emergent Biosolutions (NYSE:EBS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Emergent Biosolutions (NYSE:EBS) Income Statement, Balance Sheet and Cash Flow Statement
Emergent Biosolutions (NYSE EBS) Stock Chart for Friday, May, 25, 2018
Loading chart…
